Case Studies

One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of respiratory indications, one of which is asthma.

One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas.

One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of nephrology indications, one of which is chronic kidney disease.

PSI’s key strength is predictable patient enrollment across multiple therapeutic areas, including numerous oncology indications one of which is colorectal cancer.

One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of infectious disease indications, one of which is complicated skin & skin structure infections.

One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of auto-immune indications, one of which is gout.

PSI’s key strength is predictable patient enrollment across multiple therapeutic areas, including numerous hematology indications.

One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of infectious disease indications, one of which is hepatitis.

One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of infectious disease indications, one of which is HAP/VAP pneumonia.

One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of cardiovascular disease indications, one of which is intermittment claudication.

PSI focus on predictable patient enrollment across a variety of therapeutic areas. This includes a variety of CNS indications, one of which is multiple sclerosis. Clinical trials in this area require diligence and accuracy to recruit patients on time.

PSI’s key strength is predictable patient enrollment across multiple therapeutic areas, including numerous oncology indications one of which is lung cancer.

PSI is known for accurate, predicable patient enrollment on-time or ahead of schedule. This includes a variety of CNS indications, one of which is opioid dependence.

PSI’s key strength is predictable patient enrollment across multiple therapeutic areas, including numerous oncology indications one of which is pancreatic cancer.

One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of central nervous system (CNS) indications, one of which is Parkinson’s Dementia.

One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of cardiovascular disease indications, one of which is peripheral arterial disease.

One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of indications in pediatric patients that PSI has successful conducted , one of which was in Post Operative Nausea & Vomitting.

PSI’s key strength is predictable patient enrollment across multiple therapeutic areas, including numerous oncology indications one of which is prostate cancer.

PSI’s core strength is to predictably enroll patients across multiple therapeutic areas predictably and on-time. Previous PSI clinical trial successes include a range and depth of oncology indications, including renal cell cancer.

One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of auto-immune indications, one of which is rheumatoid arthritis.

One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of CNS indications, one of which is schizophrenia.

One of the core PSI clinical trial strengths is predictable patient enrollment across numerous therapeutic areas. This includes a variety of auto-immune indications, one of which is ulcerative colitis.

This case study is an illustration of how operational cohesion of two research organizations – The Vienna Challenge Chamber (VCC) and PSI – translates into swift progress and predictable timelines.

Early-phase clinical research in the area of respiratory tract disorders – such as asthma, allergic rhinitis (hay fever) and other atopic conditions – often warrants the use of specialized facilities.